Seelos: Positive Data in Ketamine Study

- SLS-002 Demonstrated a 76.5% Response Rate in the Primary Endpoint on MADRS 24 Hours After First Dose, with a Mean Reduction in Total Score from 39.4 to 14.5 points

- A 92.9% Response Rate was Observed in a Key Secondary Endpoint on Day 16 (after five doses), Achieving a Mean MADRS Score of 7.4 points

- Rapid, Robust, and Sustained Reduction in Suicidality was Observed by All 3 Scales Measuring Suicidality as well as MADRS Item-10

- Persistence of Effect Seen in 100% of Study Subjects on MADRS, Sheehan-Suicidality Tracking Scale and MADRS Item-10 at Day 29, 14 Days After Last Dose of SLS-002

- Seelos will Host a Conference Call Today at 8:30am ET to Discuss Results

Conference Call Information

Seelos will host a conference call today, Monday, May 17th, at 8:30am ET, to discuss the results. On the call from Seelos will be Raj Mehra, Ph.D., Chairman and CEO and Tim Whitaker, M.D., Chief Medical Officer.

Additionally, David V. Sheehan, M.D., the Distinguished University Health Professor Emeritus at the University of South Florida College of Medicine, will be on the call as well to discuss this groundbreaking data.

Dial-in and Webcast Information for Monday May 17th at 8:30am ET

Domestic: (877) 407-0789
International: (201) 689-8562
Conference ID: 13719894
Webcast: http://public.viavid.com/index.php?id=144999

https://finance.yahoo.com/news/seelos-therapeutics-announces-positive-topline-100000846.html